- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 04.08. | Gates Foundation pledges $2.5B toward women's health research | ||
| 04.08. | Drugmakers score policy win in fight against 340B | ||
| 04.08. | A brain biotech slumps even with 'best case' seizure data | ||
| 04.08. | Xoma strikes deals to buy struggling biotechs HilleVax, Lava | ||
| 04.08. | The race to scale to 1,000 liters and beyond in gene therapy manufacturing | ||
| 01.08. | Regeneron cancer bispecific rejected again; Allogene discloses trial death | ||
| 01.08. | Trump redoubles threats in attempt to strongarm drugmakers on prices | ||
| 01.08. | Experts ousted from CDC panel warn of damage to US vaccine policy | ||
| 31.07. | In rumored AbbVie deal, Wall Street sees momentum for psychedelics M&A | ||
| 31.07. | Alnylam reaches new highs on strong sales of closely watched rare disease drug | ||
| 31.07. | Venture firm Frazier closes $1.3B fund for early-stage biotech investing | ||
| 31.07. | Moderna to lay of 10% of workforce in 'difficult but necessary step' | ||
| 31.07. | Lilly's Mounjaro protects heart health in large diabetic study | ||
| 30.07. | Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval | ||
| 30.07. | Vinay Prasad's ouster leaves biotech guessing at FDA direction | ||
| 30.07. | J&J tests direct CAR-T marketing with first Carvykti ad | ||
| 29.07. | Merck plans spending shift to boost business beyond Keytruda | ||
| 29.07. | Novo cuts guidance, names new CEO as obesity drug challenges mount | ||
| 29.07. | Bavarian Nordic agrees to $3B take-private deal | ||
| 29.07. | Bain leads $300M investment in startup built on Bristol Myers immune drugs | ||
| 29.07. | Radiopharma startup Artbio secures $132M to fund testing of Pluvicto rival | ||
| 28.07. | FDA allows Sarepta to resume some Elevidys shipments | ||
| 28.07. | Adaptimmune, seeking to stay afloat, sells off cell therapies | ||
| 28.07. | Celcuity shares triple on late-stage results for breast cancer therapy | ||
| 28.07. | Atai backs away from schizophrenia drug after trial failure |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .